Literature DB >> 2841989

Liver tumours.

P P Anthony.   

Abstract

Humans are remarkably resistant to many carcinogens that readily produce liver tumours in rodents, particularly the rat. The neoplastic process has been extensively studied in animal experiments, but little is known so far of how it evolves in humans. Few drugs have been shown to cause liver tumours in humans, and the risk appears to be low. The best-known examples are C17-alkylated or ethinylated gonadal sex steroids. Oral contraceptives have now been in use by millions for thirty years, but only a few hundred cases at most of liver cell adenoma have been observed. The role of these substances in liver cell carcinoma remains controversial, and the evidence is weaker still in relation to focal nodular hyperplasia and other tumour-like conditions. Anabolic-androgenic steroids stand out as the major cause of peliosis, but liver cell tumours induced by them seem to be adenomas and not carcinomas as originally suggested. The effect that both oral contraceptives and anabolic-androgenic steroids have on liver vasculature is of great clinical importance as the most important complication of liver tumours is rupture, leading to life-threatening haemorrhage. For this reason, liver tumours arising in users of these drugs should be removed whenever feasible. Thorium dioxide will remain a risk factor for the development of angiosarcoma, liver cell carcinoma and bile duct carcinoma for some time yet, and the number of patients who have been exposed is high--tens of thousands at least. The evidence of a carcinogenic role for many other drugs is anecdotal or weak. Neoplasia in the liver seems to be the least important side-effect of drugs in clinical use.

Entities:  

Keywords:  Biology; Cancer; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Methods--side effects; Diseases; Family Planning; Hepatic Effects; Liver Neoplasms--etiology; Neoplasms; Oral Contraceptives--side effects; Physiology; Population At Risk; Research Methodology; Risk Factors

Mesh:

Substances:

Year:  1988        PMID: 2841989     DOI: 10.1016/0950-3528(88)90014-0

Source DB:  PubMed          Journal:  Baillieres Clin Gastroenterol        ISSN: 0950-3528


  4 in total

Review 1.  C1 inhibitor deficiency: consensus document.

Authors:  M M Gompels; R J Lock; M Abinun; C A Bethune; G Davies; C Grattan; A C Fay; H J Longhurst; L Morrison; A Price; M Price; D Watters
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

2.  Effects of anabolic androgenic steroids on sleep patterns of individuals practicing resistance exercise.

Authors:  Daniel Paulino Venâncio; Sergio Tufik; Silvério Aparecido Garbuio; Antonio Claudio Lucas da Nóbrega; Marco Túlio de Mello
Journal:  Eur J Appl Physiol       Date:  2007-11-28       Impact factor: 3.078

3.  Body builder's liver.

Authors:  A Klava; P Super; M Aldridge; J Horner; P Guillou
Journal:  J R Soc Med       Date:  1994-01       Impact factor: 18.000

4.  Comparative histomorphological review of rat and human hepatocellular proliferative lesions.

Authors:  Bob Thoolen; Fiebo J W Ten Kate; Paul J van Diest; David E Malarkey; Susan A Elmore; Robert R Maronpot
Journal:  J Toxicol Pathol       Date:  2012-10-01       Impact factor: 1.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.